Host immune system (RSV prefusion F protein and Influenza hemagglutinin antigens)

The host immune system is the functional target for vaccines that present Respiratory Syncytial Virus (RSV) prefusion F protein and Influenza hemagglutinin (HA) antigens to elicit protective immunity. The RSV prefusion F protein is a metastable surface glycoprotein that is the primary target for neutralizing antibodies, as it is essential for the virus to fuse with host cell membranes [1]. Influenza hemagglutinin is the principal surface antigen of the influenza virus, mediating attachment to sialic acid receptors on the respiratory epithelium [2]. Vaccines utilizing these antigens, such as mRNA-based combination candidates, aim to induce high titers of neutralizing antibodies and robust T-cell responses against both pathogens simultaneously [3]. This strategy is particularly relevant for addressing the high burden of seasonal respiratory disease in elderly and immunocompromised populations. By targeting the immune system's adaptive arm, these antigens provide a prophylactic defense mechanism that reduces the severity and incidence of RSV and influenza infections [4].

Other names

RSV/Flu combination vaccine targetRSV preF and Influenza HA antigensRespiratory Syncytial Virus and Influenza vaccine antigens

Active immunization via antigen presentation to B and T lymphocytes, inducing neutralizing antibodies against RSV F protein and Influenza hemagglutinin.